{
    "clinical_study": {
        "@rank": "35202", 
        "arm_group": [
            {
                "arm_group_label": "1.0 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 1.0 mg/kg IV every 2 weeks"
            }, 
            {
                "arm_group_label": "2.0 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 2.0 mg/kg IV every 2 weeks"
            }, 
            {
                "arm_group_label": "0.2 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 0.2 mg/kg IV every 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult\n      Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01\n      and PB-102-F02. Patients will be enrolled  to receive the same dose of PRX-102 (0.2 mg/kg,\n      1.0 mg/kg, 2.0 mg/kg), as an intravenous infusion every 2 weeks for 24 Months."
        }, 
        "brief_title": "Extension Study of PRX-102 for 24 Months", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Fabry Disease", 
        "condition_browse": {
            "mesh_term": "Fabry Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completion of study PB-102-F02\n\n          -  The patient signs informed consent\n\n          -  Female patients and male patients whose co-partners are of child-bearing potential\n             agree to use a medically acceptable method of contraception, not including the rhythm\n             method. Acceptable methods of contraception include hormonal products, intrauterine\n             device, or male or female condoms. Contraception should be used for 1 month after\n             treatment termination.\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing\n\n          -  Presence of any medical, emotional, behavioral or psychological condition that, in\n             the judgment of the Investigator and/or Medical Director, would interfere with the\n             patient's compliance with the requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981720", 
            "org_study_id": "PB-102-F03"
        }, 
        "intervention": {
            "arm_group_label": [
                "1.0 mg/kg", 
                "2.0 mg/kg", 
                "0.2 mg/kg"
            ], 
            "intervention_name": "PRX-102", 
            "intervention_type": "Drug", 
            "other_name": "chemically modified human alpha galactosidase"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 5, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients", 
        "overall_official": {
            "affiliation": "Protalix Ltd", 
            "last_name": "Einat Almon, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Treatment emergent adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Every two weeks for 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981720"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Protalix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Protalix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}